Clinical Trial Update: Fondaparinux 1,5 mg for the Prevention of Venous Thromboembolism (VTE) in Medical Patients With Renal Insufficiency [Phase 4]

View source ↗

Summary

Phase 4 trial update shows fondaparinux 1.5 mg was studied for prevention of venous thromboembolism in medical patients with renal insufficiency. The study stat…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Renal Insufficiency
• Venous Thromboembolism

Drugs mentioned

• Fondaparinux (fondaparinux)

Snippet

Sponsor: Università degli Studi dell'Insubria | Conditions: Medical Patients, Renal Insufficiency | Phase 4 | Status: TERMINATED